PRESS RELEASE 8 June 2026

Recipharm and Fusix Biotech advance novel oncolytic virus platform

- *Collaboration to advance novel oncolytic virus-based cancer immunotherapies*
- *Recipharm to support development and GMP manufacturing of Fusix Biotech's FUSE102 programme and future pipeline candidates*
- *Partnership reinforces Recipharm's expertise in oncology biologics and viral-based therapies*

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a strategic collaboration with Fusix Biotech to support the development and manufacturing of next-generation cancer immunotherapies based on innovative oncolytic virus technology.

Fusix Biotech is developing breakthrough cancer treatments using proprietary oncolytic fusion virus technology designed to combine direct tumour cell destruction with modulation of the tumour microenvironment to enhance anti-tumour immune responses.

The company's lead candidate, FUSE102, is a chimeric oncolytic virus encoding a high affinity soluble PD-1 intended to enable immune checkpoint inhibition and strengthen anti-tumour activity. The programme represents a novel approach within the rapidly evolving field of cancer immunotherapy.

Under the collaboration, Recipharm will tech transfer the FUSE102 process to support clinical development building on Recipharm's capabilities in viral vectors and advanced biologics manufacturing. Through its collaboration with iBET, who will do the initial process development, Recipharm will manufacture the Master Virus Seed and GMP clinical material for first in-human trials.

Greg Behar, CEO of Recipharm, said: "Oncolytic viruses represent one of the most promising areas in cancer immunotherapy today. We are pleased to collaborate with Fusix Biotech to help advance this innovative platform toward the clinic. This partnership reflects Recipharm's growing expertise in complex biologics and viral-based therapies, and our ability to support customers from process development through GMP manufacturing as they advance the next generation of oncology treatments."

Jennifer Altomonte, CEO and CSO of Fusix Biotech, added: "Partnering with Recipharm is an important step forward for Fusix Biotech and our InFUSE™ platform. Recipharm's experience in viral product development and biologics manufacturing makes them a strong partner as we advance our programmes toward the clinic."

This collaboration further demonstrates Recipharm's capabilities in oncology biologics, where the company supports innovators with integrated development and manufacturing services, spanning viral vectors, oncolytic viruses, nucleic acids, recombinant proteins and sterile fill and finish services. Combined with Recipharm's analytical development, process optimisation and regulatory support, these capabilities help advance complex programmes from early development through commercial manufacture.

For more information

About Fusix Biotech

Fusix Biotech is a preclinical-stage biotech company based in Munich, Germany. Fusix is developing next-generation cancer therapies designed to overcome treatment resistance in solid tumors. Leveraging its proprietary InFUSE™ platform, Fusix aims to provide optimized oncolytic viral vector-based immunotherapies that mediate multiple modes of action: direct tumor cell elimination, in situ tumor vaccination, and localized delivery of therapeutic genes to the tumor site. Through broad activity across tumor types and effective systemic application, Fusix is positioning itself to deliver durable responses for patients with aggressive cancers. The company is advancing its lead candidate towards clinical development for treatment of advanced primary liver cancer.

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.

For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com

Media contact:

Guenaelle Holloway, Head of marketing and communications
Guenaelle.Holloway@recipharm.com
+44 7730 303 708